Treatment Patterns and Survival Outcomes Before and After Access to Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma: A Single-Center Retrospective Study From 2004 to 2021

Immune checkpoint inhibitors now serve as a novel treatment option for patients facing metastatic urothelial carcinoma, particularly in the second -line setting, thereby changing the treatment paradigm. Nonetheless, the substantial attrition rates during the transition from the first -line to subsequent lines of systemic therapy may hinder the potential impact of immune checkpoint inhibitors on long-term survival outcomes for the broader population.